Multitargeted treatment of cancer cachexia

Critical Reviews in Oncogenesis

Volumn 17, Issue 3, 2012, Pages 305-314

  Madeddu, Clelia ^a   Macciò, Antonio ^b   Mantovani, Giovanni ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Sirai Hospital   (Italy)

Author keywords

Cancer cachexia; Lean body mass; Multitargeted approach; Physical activity; Quality of life

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BORTEZOMIB; CANNABINOID DERIVATIVE; CARBOCISTEINE; CARNITINE; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAHEXAENOIC ACID; DRONABINOL; FISH OIL; GESTAGEN; GHRELIN; ICOSAPENTAENOIC ACID; INDOMETACIN; INFLIXIMAB; INSULIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL; MEGESTROL ACETATE; MUSCLE PROTEIN; OXANDROLONE; POLYPHENOL DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; RETINOL; SELECTIVE ANDROGEN RECEPTOR MODULATOR; THALIDOMIDE; THIOCTIC ACID; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANOREXIA; ARTICLE; CACHEXIA; CALORIC INTAKE; CLINICAL FEATURE; DIETARY INTAKE; DRUG EFFICACY; DRUG SAFETY; EUROPE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MUSCLE MASS; MUSCLE STRENGTH; NUTRITIONAL SUPPORT; PALLIATIVE THERAPY; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPTOM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; WEIGHT GAIN; WEIGHT REDUCTION;

CACHEXIA; DRUG THERAPY, COMBINATION; HUMANS; INFLAMMATION; NEOPLASMS; PROGESTINS;

EID: 84863845976     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v17.i3.80     Document Type: Article

References (45)

1. Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006;83:1345-1350.
2. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E,Fainsinger RL, Jatoi A, Loprinzi C, Macdonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F,Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-495.
3. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89:381-410.
4. Mannie MD. T cell-mediated antigen presentation: a potential mechanism of infectious tolerance. Immunol Res. 2001;23:1-21.
5. Tisdale MJ. Catabolic mediators of cancer cachexia. Curr Opin Support Palliât Care. 2008;2:56-61.
6. Mantovani G, Maccio A, Massa E, Madeddu C. Managing cancer-related anorexia/eachexia. Drugs. 2001;61:499-514.
7. Mitch WE, Price SR. Transcription factors and muscle cachexia: is there a therapeutic target? Lancet. 2001;357:734-735.
8. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005;8:265-269.
9. Maccio A, Lai P, Santona MC, Pagliara L, Melis GB,Mantovani G. High serum levels of soluble IL-2 receptor, cytokines, and C-reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998;69:248-252.
10. Mantovani G, Maccio A, Madeddu C, Mura L, Massa E, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L. Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment. J Cell Mol Med. 2002;6:570-582.
11. Argiles JM, Lopez-Soriano FJ.The role of cytokines in cancer cachexia. Med Res Rev. 1999;19:223-248.
12. Delano MJ, Moldawer LL.The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract. 2006;21:68-81.
13. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon S, Balkwill FR. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006;176:5023-5032.
14. Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer. 2008;44:1124-11-32.
15. Reid J, McKenna HP, Fitzsimons D, McCance TV. An exploration of the experience of cancer cachexia: what patients and their families want from healthcare professionals. Eur J Cancer Care (Engl). 2010;19:682-689.
16. Mantovani G, Madeddu C, Serpe R. Improvement of physical activity as an alternative objective variable to measure treatment effects of anticachexia therapy in cancer patients. Curr Opin Support Palliât Care. 2010;4:259-265.
17. Fouladiun M, Korner U, Gunnebo L, Sixt-Ammilon P, Bosaeus I, Lundholm K. Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia. Clin Cancer Res. 2007;13:6379-6385.
18. Coss CC, Bohl CE, Dalton JT Cancer cachexia therapy: a key weapon in the fight against cancer. Curr Opin ClinNutrMetab Care.2011;14:268-273.
19. Del Fabbro E. More is better: a multimodal-ity approach to cancer cachexia. Oncologist. 2010;15:119-121.
20. Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Mailliard JA, Bushey TI, Nair S, Christensen B. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004;22:2469-2476.
21. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, KrookJE, Novotny PJ, Christensen B. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20:567-573.
22. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, KrookJE, Wilwerding MB, Rowland KM Jr, Camo-riano JK, Novotny PJ, Christensen BJ. Randomized comparison of megestrol acetate versus dexamethasone versus ffuoxymesterone for the treatment of cancer anorexia/cachexia.J Clin Oncol. 1999;17:3299-3306.
23. Simons JP, Schols AM, Hoefnagels JM, Wester-terp KR, ten Velde GP, Wouters EF Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer. 1998;82:553-560.
24. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2005(2):CD004310.
25. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer. 1974;33:1607-1609.
26. Willox JC, Corr J, Shaw J, Richardson M, Caiman KC, Drennan M. Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed). 1984;288:27.
27. Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, Gouma DJ, Giacosa A, Van Gos-sum A, Bauer J, Barber MD, Aaronson NK, Voss AC, Tisdale MJ. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003;52:1479-1486.
28. Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS,Tisdale MJ, Murray GD. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006;24:3401-3407.
29. Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev. 2007;(1):CD004597.
30. Strasser F, Luftner D, Possinger K, Ernst G, Ruh-staller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006;24:3394-3400.
31. Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, Caprioni F, Van Cutsem E, Richel D, DeWitte M, Qi M, Robinson D Jr, Zhong B, De Boer C, Lu JD, Prabhakar U, Cor-ringham R, Von Hoff D. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol. 2008;6:18-25.
32. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM.Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut. 2005;54:540-545.
33. Lai V, George J, Richey L, Kim HJ, Cannon T, Shores C, Couch M. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck. 2008;30:67-74.
34. Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D,Tschop M, Kaufmann K, Hoist B, Brandie M, von Moos R, Demmer R, Cerny T Safety, toler-ability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer. 2008;98:300-308.
35. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, Frost GS, Ghatei MA, Coombes RC, Bloom SR. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:2832-2836.
36. Garcia J. A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia. J Clin Oncol. 2007;25(Suppl):Abstract 9133.
37. Lesser GJ, Case D, Ottery F, McQuellon R, Choksi JK, Sanders G, Rosdhal R, Shaw EG. A phase III randomized study comparing the effects of oxan-drolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy. J Clin Oncol. 2008; 26(Suppl):Abstract 9513.
38. Argiles JM, Olivan M, Busquets S, Lopez-Soriano FJ. Optimal management of cancer anorexia-cachexia syndrome. Cancer Manag Res. 2010;2:27-38.
39. Argiles JM, Lopez-Soriano FJ, Busquets S. Novel approaches to the treatment of cachexia. Drug Discov Today. 2008;13:73-78.
40. Cerchietti LC, Navigante AH, Peluffo GD, Diament MJ, StilHtani I, Klein SA, Cabalar ME. Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage. 2004;27:85-95.
41. erchietti LC, Navigante AH, Castro MA. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer. 2007;59:14-20.
42. Lundholm K, Korner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, Bosaeus I. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res. 2007;13:2699-2706.
43. Mantovani G, Madeddu C, Maccio A, Grami-gnano G, Lusso MR, Massa E, Astara G, Serpe R. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev. 2004;13:1651-1659.
44. Mantovani G, Maccio A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, pro-gestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/ cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev. 2006;15:1030-1034.
45. Mantovani G, Maccio A, Madeddu C, Serpe R, Massa E, Dessi M, Panzone F, Contu P. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist. 2010;15:200-211.